The analysis of serum response factor expression in bone and soft tissue prostate cancer metastases

Prostate

Volumn 74, Issue 3, 2014, Pages 306-313

  O'Hurley, Gillian ^a,b   Prencipe, Maria ^a   Lundon, Dara ^a   O'Neill, Amanda ^a   Boyce, Susie ^a   O'Grady, Anthony ^b   Gallagher, William M ^a   Morrissey, Colm ^c   Kay, Elaine W ^b   Watson, R William G ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b BEAUMONT HOSPITAL   (Ireland)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

immunohistochemistry; prostate cancer metastases; serum response factor

Indexed keywords

SERUM RESPONSE FACTOR;

ARTICLE; BONE METASTASIS; CANCER CELL; CASTRATION RESISTANT PROSTATE CANCER; CELL PROLIFERATION; CLINICAL ARTICLE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; SOFT TISSUE TUMOR; TISSUE MICROARRAY;

EID: 84892432817     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22752     Document Type: Article

References (16)

1. O'Hurley G, Perry AS, O'Grady A, Loftus B, Smyth P, O'Leary JJ, Sheils O, Fitzpatrick JM, Hewitt SM, Lawler M, Kay EW,. The role of secreted frizzled-related protein 2 expression in prostate cancer. Histopathology 2011; 59 (6): 1240-1248.
2. Prencipe M, Madden SF, O'Neill A, O'Hurley G, Culhane A, O'Connor D, Klocker H, Kay EW, Gallagher WM, Watson WR,. Identification of transcription factors associated with castration-resistance: Is the serum responsive factor a potential therapeutic target ? Prostate 2013; 73: 743-753. doi: 10.1002/pros.22618
3. Hörnberg E, Ylitalo EB, Crnalic S, Antti H, Stattin P, Widmark A, Bergh A, Wikström P,. Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival. PLoS ONE 2011; 6: e19059.
4. Morrissey C, Roudier MP, Dowell A, True LD, Ketchanji M, Welty C, Corey E, Lange PH, Higano CS, Vessella RL,. Effects of androgen deprivation therapy and bisphosphonate treatment on bone in patients with metastatic castration-resistant prostate cancer: Results from the University of Washington Rapid Autopsy Series. J Bone Miner Res 2013; 28 (2): 333-340.
5. Sun Q, Chen G, Streb JW, Long X, Yang Y, Stoeckert CJ Jr, Miano JM,. Defining the mammalian CArGome. Genome Res 2006; 16 (2): 197-207.
6. Vickers ER, Kasza A, Kurnaz IA, Seifert A, Zeef LA, O'donnell A, Hayes A, Sharrocks AD,. Ternary complex factor-serum response factor complex-regulated gene activity is required for cellular proliferation and inhibition of apoptotic cell death. Mol Cell Biol 2004; 24 (23): 10340-10351.
7. Posern G, Treisman R,. Actin' together: Serum response factor, its cofactors and the link to signal transduction. Trends Cell Biol 2006; 16 (11): 588-596.
8. Heemers HV, Regan KM, Dehm SM, Tindall DJ,. Androgen induction of the androgen receptor coactivator four-and-a-half LIM domain protein-2: Evidence for a role for serum response factor in prostate cancer. Cancer Res 2007; 67 (21): 10592-10599.
9. Yu W, Feng S, Dakhova O, Creighton CJ, Cai Y, Wang J, Li R, Frolov A, Ayala G, Ittmann M,. FGFR-4 Arg(3)(8)(8) enhances prostate cancer progression via extracellular signal-related kinase and serum response factor signaling. Clin Cancer Res 2011; 17 (13): 4355-4366.
10. Roudier MP, True LD, Higano CS, Vesselle H, Ellis W, Lange P, Vessella RL,. Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone. Hum Pathol 2003; 34 (7): 646-653.
11. Zhang X, Morrissey C, Sun S, Ketchandji M, Nelson PS, True LD, Vakar-Lopez F, Vessella RL, Plymate SR,. Androgen receptor variants occur frequently in castration resistant prostate cancer metastases. PLoS ONE 2011; 6 (11): e27970.
12. Mendez O, Martin B, Sanz R, Aragüés R, Moreno V, Oliva B, Stresing V, Sierra A,. Underexpression of transcriptional regulators is common in metastatic breast cancer cells overexpressing Bcl-xL. Carcinogenesis 2006; 27 (6): 1169-1179.
13. Suzuki H, Freije D, Nusskern DR, Okami K, Cairns P, Sidransky D, Isaacs WB, Bova GS,. Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. Cancer Res 1998; 58 (2): 204-209.
14. Putzke AP, Ventura AP, Bailey AM, Akture C, Opoku-Ansah J, Celiktaş M, Hwang MS, Darling DS, Coleman IM, Nelson PS, Nguyen HM, Corey E, Tewari M, Morrissey C, Vessella RL, Knudsen BS,. Metastatic progression of prostate cancer and e-cadherin regulation by zeb1 and SRC family kinases. Am J Pathol 2011; 179 (1): 400-410.
15. Akfirat C, Zhang X, Ventura A, Berel D, Colangelo ME, Miranti CK, Krajewska M, Reed JC, Higano CS, True LD, Vessella RL, Morrissey C, Knudsen BS,. Tumor cell survival mechanisms in lethal metastatic prostate cancer differ between bone and soft tissue metastases. J Pathol 2013; 230 (3): 291-297.
16. Yegnasubramanian S, Haffner MC, Zhang Y, Gurel B, Cornish TC, Wu Z, Irizarry RA, Morgan J, Hicks J, DeWeese TL, Isaacs WB, Bova GS, De Marzo AM, Nelson WG,. DNA hypomethylation arises later in prostate cancer progression than CpG island hypermethylation and contributes to metastatic tumor heterogeneity. Cancer Res 2008; 68 (21): 8954-8967.